Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data

Published 17/04/2024, 17:41
© Reuters.  Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data
SAGE
-

Benzinga - by Vandana Singh, Benzinga Editor.

Wednesday, Sage Therapeutics Inc (NASDAQ:SAGE) announced topline results from the PRECEDENT Phase 2 study of dalzanemdor (SAGE-718) in people with mild cognitive impairment in Parkinson’s Disease.

The PRECEDENT Study did not meet its primary endpoint of demonstrating a statistically significant difference from baseline in participants treated with once-daily dalzanemdor versus placebo on the Wechsler Adult Intelligence Scale Fourth Edition-IV (WAIS-IV) Coding Test score at Day 42.

WAIS-IV is the most advanced adult measure of cognitive ability.

Dalzanemdor (SAGE-718) was generally well-tolerated, and no new safety signals were observed.

48 participants experienced treatment-emergent adverse events (TEAEs). The vast majority of TEAES were mild to moderate in severity.

“We are disappointed by the results of the Phase 2 PRECEDENT study given the significant burden of mild cognitive impairment on people and families affected by Parkinson’s Disease,” said Barry Greene, Chief Executive Officer at Sage Therapeutics.

Analyses did not suggest meaningful differences versus placebo in the other exploratory endpoints, such as SCOPA-Cog, a measure for assessing cognitive function.

Based on the data, the company does not plan to develop dalzanemdor (SAGE-718) further in Parkinson’s Disease.

The company expects the following milestones for the dalzanemdor (SAGE-718) Phase 2 clinical development program in 2024:

  • Topline data from the SURVEYOR Study in Huntington’s disease cognitive impairment in mid-2024.
  • Topline data from LIGHTWAVE Study in people with mild cognitive impairment and mild dementia in Alzheimer’s disease in late 2024.
  • Topline data from the DIMENSION Study in people with Huntington’s disease cognitive impairment in late 2024.
Price Action: SAGE shares are down 23.80% at $11.91 on the last check Wednesday.

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.